# Home inotrope therapy in chronic stimulant-induced cardiomyopathy: a case series

**Authors:** Max Joseph, Sejal Batra, Wali Kamran, Kelsey Barrett, Barbara Ebert, Ahmed Nassar, Timothy Misselbeck, Nael Hawwa

PMC · DOI: 10.1093/ehjcr/ytae406 · 2024-08-12

## TL;DR

Home inotrope therapy can help manage chronic stimulant-induced cardiomyopathy by stabilizing patients and aiding recovery or preparing for advanced treatments.

## Contribution

The paper introduces home inotrope therapy as a viable management option for chronic stimulant-induced cardiomyopathy.

## Key findings

- Home inotrope therapy can stabilize patients with chronic stimulant-induced cardiomyopathy.
- It serves as a bridge to advanced therapies like LVAD or heart transplantation.
- It can also act as a psychosocial stress test for future treatment decisions.

## Abstract

Patients with chronic stimulant-induced cardiomyopathy presenting with cardiogenic shock can be stabilized with conventional measures. However, their management post-stabilization has not been well described and poses unique challenges: (i) less chance of myocardial recovery compared to acute stimulant-induced cardiomyopathy, (ii) psychosocial barriers to left ventricular assist device (LVAD) and heart transplantation, and (iii) concern for use of peripherally inserted central catheter for home inotrope in those with a history of substance abuse.

Three patients with chronic stimulant-induced cardiomyopathy were admitted with cardiogenic shock progressing to Society for Cardiovascular Angiography & Interventions stage D or E. They were stabilized with inotrope and/or biventricular mechanical circulatory support. Long-term home inotrope was used as either a bridge to LVAD, reverse remodelling, or stabilization.

Home inotrope should be viewed as an option in chronic stimulant-induced cardiomyopathy on a case-by-case basis. It can buy time to allow for myocardial stabilization or recovery through goal-directed medical therapy and stimulant cessation. It can also serve as a ‘psychosocial stress test’ for future consideration of advanced heart failure therapies.

## Linked entities

- **Diseases:** cardiomyopathy (MONDO:0004994), cardiogenic shock (MONDO:0800175)

## Full-text entities

- **Diseases:** heart failure (MESH:D006333), substance abuse (MESH:D019966), cardiomyopathy (MESH:D009202), cardiogenic shock (MESH:D012770)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11336994/full.md

---
Source: https://tomesphere.com/paper/PMC11336994